文献速递血液净化与透析肾移植

慢性透析患者对SARS-CoV-2 mRNA疫苗具有高免疫原性

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

接受免疫抑制治疗是疫苗接种无应答的独立预测因素。

要点

  • 透析患者接种两剂BNT162b2后 seroconversion 率为88.7%。
  • 免疫抑制治疗是无应答的独立预测因素。
  • 建议优先完成两剂接种,无应答者可追加第三剂。

核心结论

  • 透析患者对SARS-CoV-2 mRNA疫苗具有高免疫原性,推荐优先接种两剂,无应答者需第三剂。

主要发现

  • 初始 seronegative 的97例患者中,86例(88.7%) seroconversion。
  • 接受免疫抑制治疗是无应答的独立预测因素。

关键数值与推荐

  • 两剂BNT162b2 mRNA疫苗,每剂30μg,肌肉注射,间隔28天。
  • 第二剂后仍 seronegative 者,1个月后接种第三剂。

临床怎么用

  • 优先为透析患者接种两剂mRNA疫苗。
  • 对两剂无应答者考虑第三剂。
  • 等待肾移植患者应尽可能在移植前接种疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic kidney disease, dialysis patients and kidney transplant patients are at high risk of developing severe coronavirus disease 2019 (COVID-19). Data regarding the immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (anti-SARS-CoV-2 mRNA) vaccines in dialysis patients were published recently. We assessed the immunogenicity of anti-SARS-CoV-2 mRNA vaccine in dialysis patients. PATIENTS AND METHODS: One hundred and nine patients on haemodialysis (n = 85) or peritoneal dialysis (n = 24) have received two injections of 30-μg doses of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) that were administered intramuscularly 28 days apart. Those who were still seronegative after the second dose were given a third dose 1 month later. Anti-SARS-CoV-2 antibodies were tested before and after vaccination. RESULTS: Ninety-one out of the 102 patients who had at least a 1-month follow-up after the second (n = 97) or the third (n = 5) vaccine doses had anti-SARS-CoV-2 antibodies. The seroconversion rate was 88.7% (86 out of 97 patients) among SARS-CoV-2 seronegative patients at the initiation of vaccination. Receiving immunosuppressive therapy was an independent predictive factor for non-response to vaccination. CONCLUSION: Due to high immunogenicity and safety of mRNA vaccines, we strongly recommend prioritizing a two-dose vaccination of dialysis patients. A third dose can be required in non-responders to two doses. When possible, patients waiting for a kidney transplantation should be offered the vaccine before transplantation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Longlune N, Nogier MB, Miedougé M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant. 2021. PMID: 34057463. doi:10.1093/ndt/gfab193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。